Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

benign idiopathic neonatal seizures (BINS) - Clinical Profile, Treatments & Trials | Kisho | Kisho

Rare Disease

benign idiopathic neonatal seizures

MONDO:0018981

Also known as:BINSbenign nonfamilial neonatal seizures

Overview

A rare neonatal epilepsy syndrome characterized by seizures without specific underlying etiology, occurring during the first days of life in infants with an otherwise normal neurological state and no family history of neonatal convulsions. The most commonly partial and clonic seizures usually last for one to three minutes. Repeated seizures may lead to status epilepticus lasting up to 20 hours. Overall, remission rates are high and neurological outcome is favorable.

Treatments1 FDA approved

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

1 FDA-approved treatment is available for benign idiopathic neonatal seizures, including PHENOBARBITAL SODIUM (SEZABY, approved 2022). An additional 2 compounds hold orphan drug designation.

Approved Therapies

Brand Name	Generic Name	Mechanism	Approved	Market Status

Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 1:11 PM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

External Resources

Orphanet

European rare disease database

Orphanet:64545

GARD

Genetic and Rare Diseases Info Center

GARD:18860

Questions for Your Care Team

→What are the benefits and potential side effects of SEZABY for managing benign idiopathic neonatal seizures?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

Brand Name	Generic Name	Sponsor	Designated	Exclusivity End	Designation Status
topiramate	topiramate	PrevEP Inc.	2024	—	Designated
levetiracetam	levetiracetam	University of California	2010	—	Designated

Kisho

benign idiopathic neonatal seizures

Overview

Treatment

Approved Therapies

Medical References

External Resources

Orphanet

GARD

Questions for Your Care Team

Questions for Your Care Team

Orphan Drug Designations

Clinical Trials

benign idiopathic neonatal seizures

Overview

Treatment

Approved Therapies

Medical References

External Resources

Orphanet

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Orphan Drug Designations

Clinical Trials